Evommune (EVMN) Stock Price, News & Analysis

Company Overview

Evommune, Inc. is a clinical-stage biotechnology company focused on developing new treatments for immune-mediated inflammatory diseases. The company’s research is centered on identifying therapies that address the underlying biological mechanisms driving chronic inflammation rather than primarily treating symptoms.

Evommune is advancing a pipeline of investigational medicines designed for conditions with significant unmet medical needs, including dermatologic and other inflammatory disorders. Its development programs are intended to offer differentiated approaches for patients who do not respond adequately to existing therapies.

The company does not currently market an approved commercial product, and its drug candidates remain subject to clinical development and regulatory review. Evommune is headquartered in the United States and works through research, clinical-development and biotechnology partnerships to advance its pipeline.

Key Stats

• Today's Range: $6.18 to $6.44
• 50-Day Range: $6.24 to $14.99
• 52-Week Range: $6.02 to $33.20
• Volume: 557,950 shs
• Average Volume: 897,577 shs
• Market Capitalization: $226.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $33.33
• Consensus Rating: Moderate Buy

Evommune Stock Analysis - MarketRank™

Evommune scored higher than 50% of companies evaluated by MarketBeat, and ranked 309th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Evommune has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 1 strong buy rating, 10 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

Evommune has a consensus price target of $33.33, representing about 434.0% upside from its current price of $6.24.

Amount of Analyst Coverage

Evommune has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Evommune are expected to decrease in the coming year, from ($3.29) to ($3.64) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Evommune is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Evommune is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Evommune has a P/B Ratio of 0.96. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.57% of the float of Evommune has been sold short.

Short Interest Ratio / Days to Cover

Evommune has a short interest ratio ("days to cover") of 3.86, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Evommune has recently increased by 0.56%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Evommune does not currently pay a dividend.

Dividend Growth

Evommune does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

2 people have searched for EVMN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Evommune to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Evommune insiders have not sold or bought any company stock.

Percentage Held by Insiders

31.10% of the stock of Evommune is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Evommune has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NYSE:EVMN
• CIK: 2044725
• Web: www.evommune.com
• Phone: (650) 223-7745
• Fax: N/A
• Employees: 48
• Year Founded: 2020

Price Target and Rating

• Average Price Target for Evommune: $33.33
• High Price Target: $55.00
• Low Price Target: $18.00
• Potential Upside/Downside: +434.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.73
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): ($11.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$68.87 million
• Net Margins: N/A
• Pretax Margin: -946.68%
• Return on Equity: -62.63%
• Return on Assets: -40.55%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.68
• Quick Ratio: 11.68

Sales & Book Value

• Annual Sales: $13 million
• Price / Sales: 17.42
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.52 per share
• Price / Book: 0.96

Miscellaneous

• Outstanding Shares: 36,290,000
• Free Float: 25,005,000
• Market Cap: $226.52 million
• Optionable: N/A
• Beta: N/A